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bjectives The increased frequency of very late (1 year) stent thrombosis (VLST) has raised con-
erns with regard to the safety of sirolimus-eluting stents and paclitaxel-eluting stents (PES).
ackground Experimental and preliminary clinical ﬁndings with the zotarolimus-eluting stent (ZES)
ave suggested a favorable safety proﬁle.
ethods The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents
n Patients With Coronary Artery Disease) trial is a single-blind randomized ZES versus PES clinical
rial in 1,548 patients with de novo native coronary lesions; the primary end point—9-month target
essel failure—was previously reported, annual clinical follow-up is planned for 5 years, and this re-
ort describes the 3-year outcomes.
esults The ZES compared with PES reduced target vessel failure (12.3% vs. 15.9%, hazard ratio [HR]:
.76, 95% conﬁdence interval [CI]: 0.58 to 1.00, p  0.049), myocardial infarctions (MI) (2.1% vs. 4.9%, HR:
.44, 95% CI: 0.25 to 0.80, p  0.005), and cardiac death plus MI (3.6% vs. 7.1%, HR: 0.52, 95% CI 0.32 to
.82, p  0.004). Although the overall 3-year rate of Academic Research Consortium deﬁnite/probable
tent thrombosis did not differ signiﬁcantly (1.1% vs. 1.7%, HR: 0.67, 95% CI 0.28 to 1.64, p  0.380),
LST (between 1 and 3 years) was signiﬁcantly reduced in ZES patients (1 event vs. 11 events; 0.1% vs.
.6%, HR: 0.09, 95% CI: 0.01 to 0.71, p  0.004). Ischemia-driven target lesion revascularization at 3 years
as similar with ZES versus PES (6.5% vs. 6.1%, HR: 1.10, 95% CI: 0.73 to 1.65, p  0.662).
onclusions Three-year follow-up results from the ENDEAVOR IV trial indicate similar antirestenosis
fﬁcacy but improved clinical safety associated with ZES compared with PES, due to signiﬁcantly
ewer peri-procedural and remote MIs associated with fewer VLST events. (A Randomized, Controlled
rial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus
aclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions; NCT00217269)
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1044arly drug-eluting stents (DES) are burdened with late safety
oncerns—despite significant reductions in restenosis—
specially very late stent thrombosis (VLST) (after 1 year),
hich was not previously observed with bare-metal stents
BMS) (1–5). Increased VLST imposes important clinical
ilemmas: 1) events occur out-of-hospital and uniformly result
n acute myocardial infarction (MI), repeat revascularization, or
eath (4–7); 2) the duration of dual antiplatelet therapy
DAPT) in all patients is extended to 1 year or longer, and the
ptimal timing for discontinuation is unknown (4,8); and
) premature or unanticipated interruption of DAPT might
mpose additional risks for stent thrombosis (ST) (8).
The zotarolimus-eluting stent (ZES) (Endeavor, Medtronic
ardioVascular, Santa Rosa, California) was designed to retain
the clinical anti-restenosis efficacy
observed with previous DES de-
signs (9,10). Pre-clinical studies
have demonstrated improved early
endothelialization compared with
either sirolimus-eluting stents
(SES) or paclitaxel-eluting stents
(PES) (TAXUS Express, Boston
Scientific Corporation, Natick,
Massachusetts) (11,12). Patient
studies examining surrogate safety
end points with intravascular ul-
trasound, optical coherence to-
mography, or vasomotor reactivity
assessments have similarly dem-
onstrated improved outcomes,
unlike other early DES and more
closely resembling BMS (13–16).
In the prospective, randomized,
single-blinded ENDEAVOR
IV (Randomized Comparison
of Zotarolimus- and Paclitaxel-
Eluting Stents in Patients With
Coronary Artery Disease) trial,
ZES was found to be noninfe-
rior to PES with regard to the
rimary end point of 9-month target vessel failure (TVF)
17). The purpose of this report is to highlight important
ifferences in late clinical outcomes between ZES and PES
fter 3 years of follow-up.
ethods
tudy population and procedures. The ENDEAVOR IV
tudy design, patient eligibility, clinical end points, and
rinciple outcomes at 1 and 2 years have been previously
escribed (17,18). In brief, 1,548 patients 18 of age with
single de novo native coronary lesion with a diameter
bbreviations
nd Acronyms
RC  Academic Research
onsortium
MS  bare-metal stent(s)
I  confidence interval
APT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
R  hazard ratio
I  myocardial infarction
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
T  stent thrombosis
LR  target lesion
evascularization
VF  target vessel failure
LST  very late stent
hrombosis
ES  zotarolimus-eluting
tent(s)tenosis at least 50% but 100% by visual estimate, refer- cnce vessel diameter 2.5 mm and 3.5 mm, and lesion
ength 27 mm were enrolled. Patients were treated with
25 mg of aspirin within 24 h before the procedure, which
as continued indefinitely. All patients received a loading
ose of clopidogrel of at least 300 mg before the procedure,
ollowed by 75 mg daily for at least 6 months. Continuation
f clopidogrel beyond 6 months was at the discretion of the
perator. Clinical follow-up was scheduled at 30 days and 6,
, and 12 months and then yearly through 5 years. Protocol-
pecified angiographic follow-up was scheduled at 8 months
fter procedure in a subset of 328 patients (17). The study
as approved by the Institutional Review Board at each
enter, and all patients signed informed consent before the
ndex procedure.
Patients were randomly assigned in 1:1 ratio to receive
ither ZES or PES. Patients, physicians performing
ollow-up assessments, data analysis personnel, statisticians,
ngiographic and intravascular ultrasound core laboratories,
ata safety monitoring board, and an independent clinical
vents committee were masked to stent assignments. After
ll patients underwent 1-year follow-up, randomization
odes were provided to all sites, and upon Institutional
eview Board approval, the stent information was disclosed
o patients enrolled in the study.
The primary clinical end point was TVF (the composite of
ardiac death, MI, or clinically driven target vessel revascular-
zation) at 9 months after procedure. Diagnosis of Q-wave MI
equired new pathologic Q waves in 2 contiguous electro-
ardiographic leads and either symptoms consistent with acute
yocardial ischemia or elevation of cardiac biomarkers. Non–
-wave MI required elevated creatine kinase 2 the upper
aboratory limit with elevated creatine kinase-myocardial band in
he absence of pathological Q waves. Secondary clinical end
oints included major adverse cardiac events (death, MI,
mergency coronary artery bypass grafting, or clinically driven
arget lesion revascularization [TLR]). All events, including
T (the Academic Research Consortium [ARC] definition)
19), were adjudicated by the Clinical Events Committee that
emained blinded to the type of stent at each time point during
he follow-up.
tatistical analysis. The ENDEAVOR IV trial was designed
o determine whether the primary end point (TVF at 9
onths) of ZES was noninferior to PES. The sample size
stimation was based on a noninferiority test with the
arrington-Manning approach (noninferior margin: 3.8%, al-
ha  0.05 [1-sided] significance level, with 84% statistical
ower to reject the null hypothesis of inferiority). Annual
ollow-up with reporting of key safety and effectiveness end
oints was pre-specified without adjustment for multiplicity.
Analysis was performed on an intention-to-treat basis.
aseline categorical variables were compared by chi-square
r Fisher exact tests, and baseline continuous variables were
ompared by Student t tests. Hazard ratios (HRs) and their
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10455% confidence intervals (CIs) were calculated with the Cox
roportional hazards regression model. Cumulative inci-
ence of the clinical outcomes was analyzed with Kaplan-
eier methods and compared with log-rank tests. All
nalyses were performed with SAS software (version 8.2 or
igher, SAS Institute, Cary, North Carolina).
esults
etween April 11, 2005 and June 27, 2006, 1,548 patients
ere randomized at 80 clinical sites in the U.S. to ZES or PES
Fig. 1). Baseline clinical and angiographic characteristics for
ES and PES cohorts were well matched (Table 1). Post-
rocedural in-segment minimal lumen diameter (2.22  0.47
m vs. 2.19 0.50 mm, p 0.196), percent diameter stenosis
20.47  9.54% vs. 20.97  11.12%, p  0.344), and acute
ain (1.50 mm vs. 1.26  0.51 mm, p  0.937) did not differ
ignificantly between ZES and PES treatment arms.
At 3 years, TVF occurred less frequently in patients treated
ith ZES versus PES, due largely to a significantly lower
requency of MI (Table 2, Figs. 2A and 2B). A reduction in
Is was observed at 30 days after the index procedure (0.8%
s. 2.3%, HR: 0.33, 95% CI: 0.13 to 0.84, p 0.014) and also
etween 1 and 3 years (0.6% vs. 2.3%, HR: 0.25, 95% CI: 0.08
o 0.75, p 0.007). The composite end point of cardiac death
Figure 1. Patient Disposition and Follow-Up Through 3 YearsPES  paclitaxel eluting-stent(s); ZES  zotarolimus-eluting stent(s).nd MI was also significantly lower in patients treated with
ES (Table 2, Figs. 2B and 2C).
Up to 3 years, TLR was similar in ZES and PES patients
Table 2), and the small TLR differences favoring PES at 1
ear (delta 1.2%) (17) were reduced at 3 years (delta 0.4%)
Fig. 2D). The percent of patients receiving DAPT at 3
ears for ZES and PES treatment cohorts was 48.2% versus
2.1% (p  0.174). Definite or probable ST up to 3 years
ccurred in 8 ZES patients and 12 PES patients (1.1% vs.
.7%, HR: 0.67, 95% CI: 0.28 to 1.64, p  0.380) (Table 3).
etween 1 and 3 years, definite or probable VLST occurred
n 1 ZES patient and 11 PES patients (0.1% vs. 1.6%, HR:
.09, 95% CI: 0.01 to 0.71, p  0.004) (Table 3, Fig. 3).
mong the 11 PES patients with VLST events, 6 were no
onger receiving DAPT (4 with aspirin alone, and 2 without
spirin and clopidogrel), and 9 patients had an acute MI
Fig. 4). The sole ZES patient with a VLST event was not
eceiving DAPT (without aspirin and clopidogrel) and had
n acute MI (Fig. 4).
iscussion
n the ENDEAVOR IV randomized trial, comparing ZES
ith PES, although the overall rate of ARC definite and
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1046robable ST did not differ during the initial 3 years of
ollow-up, there was a significant 1.4% absolute reduction in
he rate of ARC definite or probable VLST with ZES
ompared with PES between 1 and 3 years (corresponding
o a 91% relative risk reduction). Between 2 and 3 years, the
ate of VLST remained unchanged with ZES (0.1% at both
ime points), whereas it doubled with PES (0.8% and 1.6%)
18). Moreover, the trend toward lower rates of cardiac
eath or MI observed with ZES vs. PES at 2 years (3.4% vs.
.1%, p  0.096) became significant at 3 years (3.6% vs.
.1%, p 0.004), corresponding to 3.5% absolute reduction
A
B
C
u
m
u
la
ti
v
e
 I
n
c
id
e
n
c
e
 o
f 
M
I
0%
5%
7%
8%
10
Time after Initi
Time after Init
2%
1%
3%
4%
6%
HR 0.60 (95%CI 0.29-
p = 0.15
2.6%
1.6%
HR 0.79 (95%CI 0.56-1
p = 0.17
10
ZES
PES
No. at Risk
ZES
773
20%
9.6%
7.7%
15%
10%
5%
0%C
u
m
u
la
ti
v
e
 I
n
c
id
e
n
c
e
 o
f 
T
V
F
775
769
758
ZES
PES
No. at Risk
773
775
769
755
PES
ZES
PES
Figure 2. Time-to-Event Curves Up to 3 Years for Patients Treated With ZE
(A) Target vessel failure (TVF) (cardiac death, myocardial infarction [MI], or ischr to a 49% relative risk reduction. The striking reduction in MLST with ZES (from 11 events to 1 event) was observed
ith continued DAPT in approximately one-half the pa-
ients in both groups at 3 years. The ENDEAVOR IV trial
s consistent with other studies that indicate that continued
APT does not fully protect against VLST (20); 5 of the 12
atients with VLST were still receiving DAPT at the time
f the event. The very low frequencyof ARC definite or
robable VLST in ZES patients from the ENDEAVOR
V trial (0.1% up to 3 years) is similar to previous studies
ith BMS (6) and to a much larger pooled analysis of 2,132
ES patients from 6 studies (0.2% up to 5 years) (L. Mauri,
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1047odel, the magnitude of reduction in ST, comparing ZES
ith PES during 3-year follow-up in the ENDEAVOR IV
rial, exceeded the threshold difference (0.14% change/year
n absolute late ST) sufficiently to negate the clinical benefit
f restenosis reduction when comparing DES with BMS
21). Whether these results are generalizable to patients
ndergoing PCI with other DES is still not clear. In the
ecent 18-month report from the SORT-OUT III (Danish
rganisation for Randomised Trials with Clinical Out-
ome) randomized trial, incidence of ST increased from
.2% at 9 months to 0.5% at 18 months in patients treated
ith SES, whereas there were no additional cases of ST for
ES (22). More data are needed from studies of large
nrestricted populations, such as the PROTECT (Patient
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(C) Cardiac death or MI. (D) Target lesion revascularization. CI  conﬁdence inelated OuTcomes with Endeavor versus Cypher stenting mrial), specifically designed to compare the frequency of late
T in 8,800 “real world” patients treated with either ZES or
ES (23).
The explanation for reduced overall cardiac death and MI
n the ENDEAVOR IV trial—predominantly, fewer MIs
early and late)—seems multifactorial. In ZES patients
here was a significant decrease in periprocedural MIs (0.8%
s. 2.3%, p  0.014) that was related to improved peri-
rocedural sidebranch patency (24) and a further decrease in
Is after 1 year (0.7% vs. 2.3%, p  0.017) that paralleled
he reduction in VLST events. Importantly, these were not
insignificant” non–Q-wave MIs in the PES patients, be-
ause 47% of the peri-procedural MIs and 63% of the late
after 1 year) MIs were associated with creatine kinase-
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1048tudy limitations. This 3-year follow-up analysis from the
NDEAVOR IV trial is limited by study design factors.
he sample size required to definitively examine differences
n low event rate safety end points is several-fold greater
han the 1,548 patients in this trial. Sample size consider-
tions might also help to explain a reverse difference trend in
T up to 1 year, with higher-than-expected ST in ZES
atients (0.9%) and lower-than-expected ST in PES pa-
ients (0.1%). The patients included in the ENDEAVOR
V trial had simple- to medium-complexity coronary lesions,
nd the results pertaining to safety cannot be extended to all
atients with coronary disease. Knowledge of stent type by
atients and physicians at the completion of 1-year follow-up
ight have influenced decision-making with regard to revas-
Table 1. Baseline Clinical and Angiographic Characteristics of
Study Population
ZES PES
Patient demographic data (n  773) (n  775)
Age (yrs) 64 (11) 64 (11)
Male 517 (66.9%) 531 (68.5%)
Diabetes 241 (31.2%) 236 (30.5%)
Hypertension 614 (79.4%) 640 (82.6%)
Hyperlipidemia 629 (81.4%) 657 (84.8%)
History of smoking 479 (62.6%) 462 (60.4%)
Prior MI 161 (21.1%) 176 (23.2%)
Prior PCI 218 (28.2%) 229 (29.5%)
Prior CABG 76 (9.8%) 65 (8.4%)
Angina
Stable 281 (45.6%) 292 (47.9%)
Unstable 318 (51.6%) 304 (49.9%)
MI 17 (2.8%) 13 (2.1%)
CCS class III or IV* 309 (50.3%) 292 (47.9%)
Angiographic characteristics (n  772) (n  774)
Target vessel
Left anterior descending 326 (42.2%) 321 (41.5%)
Left circumﬂex 208 (26.9%) 202 (26.1%)
Right coronary 238 (30.8%) 251 (32.4%)
Type B2/C lesion 537 (69.6%) 549 (70.9%)
Number of diseased, native, major
epicardial coronary vessels
(50% stenosis)
Single 424 (54.9%) 443 (57.2%)
Double 221 (28.6%) 202 (26.1%)
Triple 127 (16.5%) 129 (16.7%)
Left ventricular ejection fraction 57.3 (9.9) 57.5 (10.3)
Reference vessel diameter (mm) 2.73 (0.47) 2.70 (0.46)
Lesion length (mm) 13.41 (5.67) 13.80 (6.09)
Minimum lumen diameter (mm) 0.96 (0.40) 0.93 (0.40)
Percent diameter stenosis 64.83 (13.29) 65.68 (13.10)
Data are presented as mean (SD) or n (%). *Canadian Cardiovascular Society (CCS) angina class.
CABG  coronary artery bypass surgery; MI  recent myocardial infarction (72 h); PCI 
percutaneous coronary intervention; PESpaclitaxel eluting-stent(s); ZES zotarolimus-eluting
stent(s).ularization and duration of antiplatelet therapy.onclusions
otwithstanding the limitations, the ENDEAVOR IV trial
s the first randomized trial comparing different DES that
emonstrates a significant improvement in both VLST and
Table 2. Clinical Outcomes at 3 Years
ZES PES HR* (95% CI)
Log-Rank
p Value
Death
At 3 yrs 29 (4.0%) 33 (4.5%) 0.88 (0.54–1.45) 0.623
Between 1 and 3 yrs 21 (3.0%) 25 (3.5%) 0.84 (0.47–1.51) 0.566
Cardiac death
At 3 yrs 12 (1.7%) 17 (2.4%) 0.71 (0.34–1.49) 0.360
Between 1 and 3 yrs 8 (1.1%) 13 (1.8%) 0.62 (0.26–1.49) 0.281
Myocardial infarction
At 3 yrs 16 (2.1%) 36 (4.9%) 0.44 (0.25–0.80) 0.005
Between 1 and 3 yrs 4 (0.6%) 16 (2.3%) 0.25 (0.08–0.75) 0.007
Q-wave
At 3 yrs 3 (0.4%) 5 (0.7%) 0.60 (0.14–2.53) 0.485
Between 1 and 3 yrs 1 (0.1%) 4 (0.6%) 0.25 (0.03–2.25) 0.182
Non–Q-wave
At 3 yrs 13 (1.7%) 31 (4.2%) 0.42 (0.22–0.80) 0.006
Between 1 and 3 yrs 3 (0.4%) 12 (1.7%) 0.25 (0.07–0.89) 0.020
Cardiac death or
myocardial
infarction
At 3 yrs 27 (3.6%) 52 (7.1%) 0.52 (0.32–0.82) 0.004
Between 1 and 3 yrs 11 (1.5%) 28 (4.0%) 0.39 (0.20–0.80) 0.006
Target lesion
revascularization
At 3 yrs 48 (6.5%) 44 (6.1%) 1.10 (0.73–1.65) 0.662
Between 1 and 3 yrs 14 (2.0%) 19 (2.7%) 0.74 (0.37–1.48) 0.389
Target vessel
revascularization
At 3 yrs 73 (9.9%) 80 (10.9%) 0.91 (0.66–1.25) 0.568
Between 1 and 3 yrs 26 (3.7%) 28 (4.0%) 0.94 (0.55–1.60) 0.806
Nontarget lesion,
target vessel
revascularization
At 3 yrs 35 (4.9%) 50 (6.8%) 0.69 (0.45–1.07) 0.095
Between 1 and 3 yrs 16 (2.3%) 18 (2.6%) 0.90 (0.46–1.80) 0.746
Target vessel failure
At 3 yrs 91 (12.3%) 118 (15.9%) 0.76 (0.58–1.00) 0.049
Between 1 and 3 yrs 33 (4.6%) 45 (6.3%) 0.74 (0.47–1.15) 0.180
Major adverse cardiac
events
At 3 yrs 84 (11.3%) 101 (13.6%) 0.83 (0.62–1.11) 0.197
Between 1 and 3 yrs 35 (5.0%) 50 (7.0%) 0.70 (0.45–1.08) 0.103
All revascularization
At 3 yrs 155 (21.0%) 166 (22.4%) 0.92 (0.74–1.15) 0.458
Between 1 and 3 yrs 50 (7.1%) 47 (6.7%) 1.07 (0.72–1.60) 0.728
Number of patients with events, (%) is the cumulative incidence rate. *Hazard ratio (HR) and 95%
confidence interval (CI) are calculated by Cox regression model.Abbreviations as in Table 1.
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1049mportant clinical safety end points—cardiac death and MI.
urther studies are necessary to substantiate these findings
nd to determine whether ZES (like BMS) manifest main-
ained safety with reduced duration or premature with-
rawal of DAPT.
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Figure 3. Cumulative Incidence of ARC Definite and Probable ST From 1 to
Table 3. Stent Thrombosis to 3 Years
ZES
(n  734)
PES
(n  734)
HR
(95% CI)
Log-Rank
p Value
Cumulative (0–3 yrs)
Deﬁnite 6 (0.8%) 7 (1.0%) 0.86 (0.29–2.57) 0.792
Probable 2 (0.3%) 5 (0.7%) 0.40 (0.08–2.07) 0.260
Possible 8 (1.1%) 10 (1.4%) 0.80 (0.32–2.04) 0.645
Deﬁnite/probable 8 (1.1%) 12 (1.7%) 0.67 (0.28–1.64) 0.380
Any 16 (2.2%) 22 (3.0%) 0.73 (0.39–1.40) 0.343
Very late (1–3 yrs)
Deﬁnite 1 (0.1%) 6 (0.8%) 0.17 (0.02–1.39) 0.060
Probable 0 (0.0%) 5 (0.7%) 0.00 (0.00–0.00) 0.026
Possible 5 (0.7%) 7 (1.0%) 0.72 (0.23–2.27) 0.571
Deﬁnite/probable 1 (0.1%) 11 (1.6%) 0.09 (0.01–0.71) 0.004
Any 6 (0.8%) 18 (2.6%) 0.33 (0.13–0.84) 0.015
Data expressed as n (%); n  number of events at 3 years, (%) is the cumulative incidence rate.
Hazard ratios and 95% CIs are calculated with the Cox regression model.
Abbreviations as in Tables 1 and 2.ARC  Academic Research Consortium; ST  stent thrombosis; other abbreviationsutions of Manuela Negoita, MD, for overall leadership
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lei Liu, PhD, for review of all analyses for this manu-
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uthor documents, creation of print-ready figures, and
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he design, execution, and analysis of results from the
NDEAVOR IV trial.
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abbreviations as in Figures 1, 2 and 3.  732  
  734  
3 Yeas in Figures 1 and 2.
R
C
f
p
A
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 0 , 2 0 1 0
O C T O B E R 2 0 1 0 : 1 0 4 3 – 5 0
Leon et al.
The ENDEAVOR IV 3-Year Results
1050eprint requests and correspondence: Dr. Martin B. Leon,
olumbia University College of Physicians and Surgeons, Center
or Interventional Vascular Therapy, New York-Presbyterian Hos-
ital/Columbia University Medical Center, 173 Fort Washington
venue, Heart Center, 2nd Floor, New York, New York 10032.
-mail: mleon@crf.org.
EFERENCES
1. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
2. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after
implantation of first-generation drug-eluting stents: a cause for con-
cern. Circulation 2007;115:1440–5.
3. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T,
Wallentin L. Long-term outcomes with drug-eluting stents versus
bare-metal stents in Sweden. N Engl J Med 2007;356:1009–19.
4. Hodgson JM, Stone GW, Lincoff AM, et al., Society for Cardiovas-
cular Angiography and Interventions. Late stent thrombosis: consid-
erations and practical advice for the use of drug-eluting stents: a report
from the Society for Cardiovascular Angiography and Interventions
Drug-eluting Stent Task Force. Catheter Cardiovasc Interv 2007;69:
327–33.
5. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus-
and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998–1008.
6. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern
era: a pooled analysis of multicenter coronary stent clinical trials.
Circulation 2001;103:1967–71.
7. Reynolds MR, Rinaldi MJ, Pinto DS, Cohen DJ. Current clinical
characteristics and economic impact of subacute stent thrombosis.
J Invasive Cardiol 2002;14:364–8.
8. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and
outcomes of premature discontinuation of thienopyridine therapy after
drug-eluting stent placement: results from the PREMIER registry.
Circulation 2006;113:2803–9.
9. Whelan DM, van der Giessen WJ, Krabbendam SC, et al. Biocom-
patibility of phosphorylcholine coated stents in normal porcine coro-
nary arteries. Heart 2000;83:338–45.
0. Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting
stents. Adv Drug Deliv Rev 2006;58:437–46.
1. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug
eluting stents: importance of delayed healing. Arterioscler Thromb
Vasc Biol 2007;27:1500–10.
2. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The
significance of preclinical evaluation of sirolimus-, paclitaxel-, and
zotarolimus-eluting stents. Am J Cardiol 2007;100:36M–44M.
3. Miyazawa A, Ako J, Hongo Y, et al., ENDEAVOR III Investigators.
Comparison of vascular response to zotarolimus-eluting stent versus
sirolimus-eluting stent: intravascular ultrasound results from
ENDEAVOR III. Am Heart J 2008;155:108–13. z4. Awata M, Nanto S, Uematsu M, et al. Angioscopic comparison of
neointimal coverage between zotarolimus- and sirolimus-eluting stents.
J Am Coll Cardiol 2008;52:789–90.
5. Kim JS, Jang IK, Fan C, et al. Evaluation in 3 months duration of
neointimal coverage after zotarolimus-eluting stent implantation by
optical coherence tomography. The ENDEAVOR OCT Trial. J Am
Coll Cardiol Intv 2009;2:1240–7.
6. Shin DI, Seung KB, Kim PJ, et al. Long-term coronary endothelial
function after zotarolimus-eluting stent implantation. Int Heart J
2008;49:639–52.
7. Leon MB, Mauri L, Popma JJ, et al., ENDEAVOR IV Investigators.
A randomized comparison of the Endeavor zotarolimus-eluting stent
versus the TAXUS paclitaxel-eluting stent in de novo native coronary
lesions 12-month outcomes from the ENDEAVOR IV Trial. J Am
Coll Cardiol 2010;55:543–54.
8. Leon MB, Kandzari DE, Eisenstein EL, et al., ENDEAVOR IV
Investigators. Late safety, efficacy, and cost-effectiveness of a
zotarolimus-eluting stent compared with a paclitaxel-eluting stent in
patients with de novo coronary lesions: 2-year follow-up from the
ENDEAVOR IV trial (Randomized, Controlled Trial of the
Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System
Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De
Novo Native Coronary Artery Lesions). J Am Coll Cardiol Interv
2009;2:1208–18.
9. Cutlip DE, Windecker S, Mehran R, et al., on behalf of the Academic
Research Consortium. Academic Research Consortium. Clinical end-
points in coronary stent trials: a case for standardized definitions.
Circulation 2007;115:2344–51.
0. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT,
Serruys PW. Late angiographic stent thrombosis (LAST) events with
drug-eluting stents. J Am Coll Cardiol 2005;45:2088–92.
1. Garg P, Cohen DJ, Gaziano T, Mauri L. Balancing the risks of
restenosis and stent thrombosis in bare-metal versus drug-eluting
stents: results of a decision analytic model. J Am Coll Cardiol
2008;51:1844–53.
2. Rasmussen K, Maeng M, Kaltoft A, et al., SORT OUT III study
group. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting
coronary stents in routine clinical care (SORT OUT III): a randomised
controlled superiority trial. Lancet 2010;375:1090–9.
3. Camenzind E, Wijns W, Mauri L, et al. Rationale and design of the
Patient Related OuTcomes with Endeavor versus Cypher stenting
Trial (PROTECT): randomized controlled trial comparing the inci-
dence of stent thrombosis and clinical events after sirolimus or
zotarolimus drug-eluting stent implantation. Am Heart J 2009;158:
902–9.
4. Popma JJ, Mauri L, Kirtane A, Cutlip D, Almonacid A, Leon MB.
Frequency and clinical consequences associated with sidebranch occlu-
sion during stent implantation using zotarolimus-eluting and
paclitaxel-eluting coronary stents. Circ Cardiovasc Interv 2009;2:
133–9.
ey Words: randomized  very late stent thrombosis 
otarolimus.
